Killing lung cancer cells at cell-cycle phase by a new indium-111-bleomycin complex.
The efficacy of killing small cell lung cancer (SCLC) cells at the G1, S, and G2-M phase of the cell-cycle by a new 111In-bleomycin complex (111In-BLMC) was investigated. SCLC cells (N417, H526, H209) were synchronized by double thymidine block and assessed by DNA content with flow cytometry, and the period for the maximal accumulation of cells in S, G1, or G2-M phase was determined. Cells in different cell cycle phases were exposed to 0.9% NaCl, BLM, or 111In-BLMC for 1 hour and observed for colony formation. The survival of H526 cells treated with 111In-BLMC was 71% (for enriched S phase), 46% (G1), and 31% (G2-M). For N417 cells, it was 25% (S), 20% (G1), and 8% (G2-M) for 111In-BLMC and 18% (S), 33% (G1), and 10% (G2-M) for BLM. These results indicated that SCLC cells in G2-M were most sensitive and those in S phase were least sensitive to 111In-BLMC; cells in G1 phase were the least sensitive to BLM.
Hou
D Y
DY
Department of Radiation Medicine, University of Kentucky Medical Center, Lexington.
Ordonez
J V
JV
Cross
R J
RJ
Ross
D D
DD
Maruyama
Y
Y
D001761:Bleomycin / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000473:pathology; D002453:Cell Cycle; D002460:Cell Line; D002470:Cell Survival; D003584:Cytological Techniques; D004354:Drug Screening Assays, Antitumor; D005434:Flow Cytometry; D006801:Humans; D066298:In Vitro Techniques; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000473:pathology
D007205:Indium Radioisotopes; D001761:Bleomycin